We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Genes Discovered Influence Risk of Developing Leprosy

By LabMedica International staff writers
Posted on 25 Mar 2015
Print article
Image: Histopathology of tuberculoid leprosy in a skin section (Photo courtesy Dr. D.S. Ridley, Wellcome Images).
Image: Histopathology of tuberculoid leprosy in a skin section (Photo courtesy Dr. D.S. Ridley, Wellcome Images).
Leprosy, a chronic dermatological and neurological disease, is caused by infection with Mycobacterium leprae, and its manifestation, progression and prognosis are strongly associated with the proficiency of the patient's immune system.

The ability to predict the risk of contracting leprosy can help guide decisions made by public healthcare policymakers when drafting preventative measures for high-risk medical staff working in close contact with leprosy patients.

Scientists at the Genome Institute of Singapore (A*STAR, Singapore) conducted a three-stage genome-wide association studies (GWAS) of leprosy in the Chinese population. The genome-wide discovery analysis (stage 1) involved two independent data sets: a previously published GWAS data set of 706 leprosy cases, 1,225 healthy controls and 4,362 individuals with immune-related diseases as population controls from northern China of Chinese Han descent and a new unpublished data set of 842 leprosy cases and 925 controls from northern and southern China.

The second independent study was genotyped using Human 660K-Quad BeadChips (Illumina; San Diego, CA, USA). The scientists discovered six new susceptibility loci, and further gene prioritization analysis of these loci implicated Basic Leucine Zipper Transcription Factor, ATF-Like 3 (BATF3), Coiled-Coil Domain Containing 88B (CCDC88B) and Class II, major histocompatibility complex, transactivator-Suppressor of cytokine signaling 1 (CIITA-SOCS1) as new susceptibility genes for leprosy. They found the same genes linked to leprosy susceptibility also affect the level of aggression expressed by the immune system observed in autoimmune and inflammatory diseases. A person with an overly-aggressive immune system may have a good defense against infection, but stands a higher risk of developing autoimmune diseases where one's own white blood cells attack healthy cells that can lead to death in severe cases.

Jianjun Liu, PhD, a professor and lead author of the study, said, “Although commonly viewed as a medieval affliction, leprosy remains a major health problem in developing countries, claiming over 200,000 new patients worldwide annually with two to three million people permanently disabled. With the discovery of more gene variants that affect the risk of developing leprosy, we can develop better diagnostic, treatment and preventive strategies to one day eradicate leprosy permanently.” The study was published online on February 3, 2015, in the journal Nature Genetics.

Related Links:

Genome Institute of Singapore
Illumina


New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Hemoglobin Testing System
VARIANTnbs

Print article

Channels

Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Industry

view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
LGC Clinical Diagnostics